Intestinal Research

Corrigendum

Corrigendum: Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients: Keiji Yagisawa, Taku Kobayashi, Ryo Ozaki, Shinji Okabayashi, Takahiko Toyonaga, Miki Miura, Mari Hayashida, Eiko Saito, Masaru Nakano, Hajime Matsubara, Tadakazu Hisamatsu, Toshifumi Hibi; Intest Res 2020;18(3):343-344. Published online July 20, 2020; DOI: https://doi.org/10.5217/ir.2018.00078-c1; Corrects: Intest Res 2019;17(1):87

PDF PubReader ePub

5,980 View
111 Download

Original Articles

IBD

Randomized, crossover questionnaire survey of acceptabilities of controlled-release mesalazine tablets and granules in ulcerative colitis patients: Keiji Yagisawa, Taku Kobayashi, Ryo Ozaki, Shinji Okabayashi, Takahiko Toyonaga, Miki Miura, Mari Hayashida, Eiko Saito, Masaru Nakano, Hajime Matsubara, Tadakazu Hisamatsu, Toshifumi Hibi; Intest Res 2019;17(1):87-93. Published online December 14, 2018; DOI: https://doi.org/10.5217/ir.2018.00078; Correction in: Intest Res 2020;18(3):343

Abstract PDF PubReader ePub

Background/Aims
Oral mesalazine is an important treatment for ulcerative colitis (UC), and non-adherence to mesalazine increases the risk of relapse. Controlled-release (CR) mesalazine has 2 formulations: tablets and granules. The relative acceptabilities of these formulations may influence patient adherence; however, they have not been compared to date. This study aimed to evaluate the acceptabilities of the 2 formulations of CR mesalazine in relation to patient adherence using a crossover questionnaire survey.
Methods
UC patients were randomly assigned to 2 groups in a 1:1 ratio. Patients in each group took either 4 g of CR mesalazine tablets or granules for 6 to 9 weeks, and then switched to 4 g of the other formulation for a further 6 to 9 weeks. The acceptability and efficacy were evaluated by questionnaires, and adherence was assessed using a visual analog scale. The difference in acceptabilities between the 2 formulations and its impact on adherence were assessed.
Results
A total of 49 patients were prospectively enrolled and 33 patients were included in the analysis. Significantly more patients found the tablets to be less acceptable than the granules (76% vs. 33%, P=0.0005). The granules were preferable to the tablets when the 2 formulations were compared directly (73% vs. 21%, P=0.004), for their portability, size, and numbers of pills. The adherence rate was slightly better among patients taking the granules (94% vs. 91%) during the observation period, but the difference was not significant (P=0.139).
Conclusions
CR mesalazine granules are more acceptable than tablets, and may therefore be a better option for long-term medication.

Citations

Citations to this article as recorded by

Optimizing 5-aminosalicylate for moderate ulcerative colitis: expert recommendations from the Asia-Pacific, Middle East, and Africa Inflammatory Bowel Disease Coalition
Filiz Akyüz, Yoon Kyo An, Jakob Begun, Satimai Aniwan, Huu Hoang Bui, Webber Chan, Chang Hwan Choi, Nazeer Chopdat, Susan J Connor, Devendra Desai, Emma Flanagan, Taku Kobayashi, Allen Yu-Hung Lai, Rupert W Leong, Alex Hwong-Ruey Leow, Wai Keung Leung, Ju
Intestinal Research.2025; 23(1): 37. CrossRef
Non-Adherence Rate to Oral Mesalamine in Ulcerative Colitis Patients: A Systematic Review with Meta-Analysis
Cristiano Pagnini, Elisabetta Antonelli, Barbara Scrivo, Maria Cappello, Marco Soncini, Roberto Vassallo, Giammarco Mocci, Maria Carla Di Paolo
Journal of Personalized Medicine.2025; 15(4): 123. CrossRef
Shared decision-making improves adherence to mesalamine in ulcerative colitis: A prospective, multicenter, non-interventional cohort study in Germany
Wolfgang Kruis, Petra Jessen, Julia Morgenstern, Birgitta Reimers, Nike Müller-Grage, Bernd Bokemeyer
World Journal of Gastroenterology.2025;[Epub] CrossRef
Prospective Questionnaire Survey on Adherence to Oral 5‐Aminosalicylic Acid in Patients With Ulcerative Colitis
Tsuyoshi Beppu, Fumihito Hirai, Kensei Ohtsu, Masahiro Kishi, Teruyuki Takeda, Shigeyoshi Yasukawa, Noritaka Takatsu, Takashi Hisabe, Toshiharu Ueki, Kenshi Yao
JGH Open.2025;[Epub] CrossRef
Patent Landscaping of Time-dependent Mesalamine Prolonged-release Granules: A Case Study for Generic Formulation Development
Ayush Rohila, Ankit Kumar, Prakash Kumar Sirvi, Sadhana Dhyagala, Sakshi Kunjir, Rajkumar Malayandi
Journal of Pharmaceutical Innovation.2025;[Epub] CrossRef
Health-related quality of life, work productivity, and persisting challenges in treated ulcerative colitis patients: a Japanese National Health and Wellness Survey
Sakiko Hiraoka, Zhezhou Huang, Fei Qin, Fatima Megala Nathan Arokianathan, Kiran Davé, Shweta Shah, Hyunchung Kim
Intestinal Research.2025; 23(4): 524. CrossRef
Continuing or stopping 5‐aminosalicylates in patients with inflammatory bowel disease on anti‐TNF therapy: A nationwide population‐based study
Jeongkuk Seo, Seonok Kim, Seung Wook Hong, Sung Wook Hwang, Sang Hyoung Park, Dong‐Hoon Yang, Jeong‐Sik Byeon, Seung‐Jae Myung, Suk‐Kyun Yang, Ye‐Jee Kim, Byong Duk Ye
Alimentary Pharmacology & Therapeutics.2024; 60(3): 389. CrossRef
A review on taste masked multiparticulate dosage forms for paediatric
Khater AL-Japairai, Samah Hamed Almurisi, Abd Almonem Doolaanea, Syed Mahmood, Fawaz Alheibshy, Ahmed Alobaida, Nadiya Abdul-Halim, Bappaditya Chatterjee
International Journal of Pharmaceutics.2023; 632: 122571. CrossRef
Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey
Xavier Hébuterne, Stephan R Vavricka, Helen C Thorne, Lara MacKenzie-Smith, Raphaël Laoun, Johan Burisch
Inflammatory Intestinal Diseases.2023; 8(1): 41. CrossRef
Efficacy and Safety of Vitamin D Adjuvant Therapy for Ulcerative Colitis: A Meta-Analysis
Xinyi Guo, Changxing Liu, Yahui Huang, Naeem Jan
Computational and Mathematical Methods in Medicine.2022; 2022: 1. CrossRef
Factors Associated with Self-reported Medication Adherence in Japanese Community-dwelling Elderly Individuals: The Nakajima Study
Natsuko Ishida, Yurina Tokumoto, Yukio Suga, Moeko Noguchi-Shinohara, Chiemi Abe, Sohshi Yuki-Nozaki, Ayaka Mori, Mai Horimoto, Koji Hayashi, Kazuo Iwasa, Masami Yokogawa, Mai Ishimiya, Hiroyuki Nakamura, Kiyonobu Komai, Ryo Matsushita, Junko Ishizaki, Ma
YAKUGAKU ZASSHI.2021; 141(5): 751. CrossRef
Treatment of inflammatory bowel diseases: focusing on 5-aminosalicylates and immunomodulators
You Sun Kim
Journal of the Korean Medical Association.2021; 64(9): 596. CrossRef
Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef
Association of Self-Reported Medication Adherence with Potentially Inappropriate Medications in Elderly Patients: A Cross-Sectional Pilot Study
Motoyasu Miyazaki, Masanobu Uchiyama, Yoshihiko Nakamura, Koichi Matsuo, Chika Ono, Miwa Goto, Ayako Unoki, Akio Nakashima, Osamu Imakyure
International Journal of Environmental Research and Public Health.2020; 17(16): 5940. CrossRef
Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation
Satoshi Tamura, Natsuki Ishida, Takahiro Miyazu, Shunya Onoue, Shinya Tani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Takahisa Furuta, Ken Sugimoto
Scientific Reports.2020;[Epub] CrossRef

11,782 View
380 Download
14 Web of Science
15 Crossref

IBD

Evaluation of the drug-induced lymphocyte stimulation test for diagnosing mesalazine allergy: Daisuke Saito, Mari Hayashida, Taro Sato, Shintaro Minowa, Osamu Ikezaki, Tatsuya Mitsui, Miki Miura, Akihito Sakuraba, Tadakazu Hisamatsu; Intest Res 2018;16(2):273-281. Published online April 30, 2018; DOI: https://doi.org/10.5217/ir.2018.16.2.273

Abstract PDF PubReader ePub

<b>Background/Aims</b><br/>

Mesalazine is an effective drug for treating ulcerative colitis (UC), but causes allergic symptoms in a few cases. Therefore, the objective of this study was to evaluate the usefulness of the drug-induced lymphocyte stimulation test (DLST) for the diagnosis of mesalazine allergy.

Methods

Patients with UC treated with mesalazine with or without a history of associated adverse events (AEs) were enrolled at Kyorin University Hospital from July 2016 to April 2017.

Results

The DLST was performed in 104 patients with UC, of which 24 had a history of AEs due to mesalazine treatment. The control value of DLST was 337.4±296.3 counts per minute (cpm) in the AE⁺ group and 408.0±371.9 cpm in the AE⁻ group. The measured value of DLST was 578.8±424.7 cpm in the AE⁺ group and 476.5±471.8 cpm in the AE⁻ group. The stimulation index (SI) was 243.9%±291.1% in the AE⁺ group and 119.8%±53.0% in the AE⁻ group. The SI value and DLST positivity were significantly higher in the AE⁺ group than in the AE⁻ group (P=0.030 and P=0.029, respectively). The test sensitivity and specificity were 0.240 and 0.805, respectively, and the false-positive and false-negative rate was 0.195 and 0.760, respectively.

Conclusions

The DLST for mesalazine showed low sensitivity and high specificity, suggesting that it may be useful for the definitive diagnosis of allergy to mesalazine.

Citations

Citations to this article as recorded by

Evaluation of drug-induced lymphocyte stimulation test in mesalazine-associated allergic drug reaction
Naoto Fukasawa, Hiroki Kiyohara, Takeya Adachi, Shinya Sugimoto, Yusuke Yoshimatsu, Soichiro Murakami, Ichiro Mizushima, Yuta Kaieda, Kaoru Takabayashi, Junya Tsunoda, Nobuhiro Nakamoto, Koichi Fukunaga, Masataka Taguri, Yohei Mikami, Takanori Kanai
Journal of Allergy and Clinical Immunology: Global.2026; 5(2): 100625. CrossRef
Ultrasonographic features of 5-aminosalicylic acid intolerance in pediatric ulcerative colitis
Hirotoki Murashige, Yasufumi Sakata, Yoshihiro Azuma, Shunji Hasegawa
Clinical and Experimental Pediatrics.2026; 69(6): 524. CrossRef
Ulcerative Colitis with Acute Pericarditis after Dose Escalation of Mesalazine
Jun Wada, Kazumasa Kawashima, Michio Onizawa, Naohiko Gunji, Yu Watahiki, Chiharu Sakuma, Mai Murakami, Tomoaki Mochimaru, Shunsuke Miura, Hiromasa Ohira
Internal Medicine.2025; 64(14): 2165. CrossRef
Novel desensitization therapy of mesalamine intolerance in patients with ulcerative colitis
Kenji Kinoshita, Shintaro Sawaguchi, Kai Toyoshima, Sonoe Yoshida, Takahiro Yamamura, Kosuke Nagai, Ikko Tanaka, Kazuteru Hatanaka, Yoshiya Yamamoto, Hirohito Naruse, Takehiko Katsurada, Naoya Sakamoto
Gastroenterología y Hepatología.2025; 48(7): 502347. CrossRef
Hydralazine‐Induced ANCA Vasculitis Presenting With Pericarditis: A Novel Case and Literature Review
Ahmed Sami Hammami, Osejie Oriaifo, Sinda Hidri, Sukhvir Singh, Husam El Sharu, Joshua Peltz, Soroush Nomigolzar, Kunjan Udani, Aiden Abidov
Case Reports in Cardiology.2025;[Epub] CrossRef
Secondary loss‐of‐response associated with intolerance to Janus kinase inhibitor in a boy with ulcerative colitis
Yuka Minoura, Koji Yokoyama, Yuko Okada, Shinya Fukuda, Hideki Kumagai
Pediatrics International.2025;[Epub] CrossRef
Tenapanor‒induced drug eruption in hemodialysis patient： A case report
Hisato Shima, Hiroyoshi Nakatsuji, Manabu Sakaki, Yoshihide Murakami, Takumi Hamao
Nihon Toseki Igakkai Zasshi.2025; 58(4): 215. CrossRef
A Rare Case of Asymmetric Periorbital Edema due to Delayed Hypersensitivity Reaction to Thyroid Hormone Replacement
Quynh Nguyen, Hoang V.K. Dinh, Vien Phan, Nguyet Nguyen, Quan Nguyen, Van Phan
AACE Endocrinology and Diabetes.2025; 12(1): 50. CrossRef
Cutaneous Adverse Events Following Nemolizumab Administration: A Review
Yoshihito Mima, Masako Yamamoto, Ken Iozumi
Journal of Clinical Medicine.2025; 14(9): 3026. CrossRef
Novel desensitization therapy of mesalamine intolerance in patients with ulcerative colitis
Kenji Kinoshita, Shintaro Sawaguchi, Kai Toyoshima, Sonoe Yoshida, Takahiro Yamamura, Kosuke Nagai, Ikko Tanaka, Kazuteru Hatanaka, Yoshiya Yamamoto, Hirohito Naruse, Takehiko Katsurada, Naoya Sakamoto
Gastroenterología y Hepatología (English Edition).2025; 48(7): 502347. CrossRef
Effectiveness of granulocyte and monocyte adsorptive apheresis in patients with ulcerative colitis and 5-aminosalicylate intolerance
Masaki Kato, Masaki Yamashita, Shigeki Kojima, Mitsuto Tsukui, Yoshihiko Iijima, Kenichi Araki, Jun Ishida, Takumi Komatsu, Yusuke Nakamoto, Akiyo Kawashima, Maki Konno, Hirofumi Kiyokawa, Yoshinori Sato, Tsutomu Sakurada, Tadateru Maehata, Hiroshi Yasuda
Medicine.2025; 104(31): e43389. CrossRef
Elevated Serum Protease 3 Antineutrophil Cytoplasmic Antibody in Mesalazine-Intolerant Ulcerative Colitis: A Potential Diagnostic Biomarker
Yuhei Oyama, Takashi Taida, Yoshiki Matsubara, Tomomi Ozaki, Takuya Ohashi, Toshiyuki Ito, Shohei Mukai, Nobuaki Shu, Yushi Koshibu, Yusuke Ozeki, Makoto Furuya, Yukiyo Mamiya, Hayato Nakazawa, Ryosuke Horio, Chihiro Goto, Satsuki Takahashi, Akane Kurosug
Journal of Clinical Medicine.2025; 14(19): 7019. CrossRef
Significance of the drug-induced lymphocyte stimulation test for various oral mesalamines in ulcerative colitis with mesalamine intolerance
Akira Madarame, Masakatsu Fukuzawa, Kumiko Uchida, Tadashi Ichimiya, Sakiko Naito, Yoshiya Yamauchi, Takashi Morise, Yasuyuki Kagawa, Takahiro Muramatsu, Takao Itoi, Mohammed Misbah Ul Haq
PLOS One.2025; 20(10): e0334969. CrossRef
Drug-induced Interstitial Nephritis in a Patient with Ulcerative Colitis Treated with 5-Aminosalicylic Acid
Daichi Hayashi, Tsutomu Nishida, Naoto Osugi, Yasuo Kusunoki, Satoru Okabe, Yoshifumi Fujii, Dai Nakamatsu, Kengo Matsumoto, Masashi Yamamoto, Koji Fukui
Internal Medicine.2024; 63(8): 1081. CrossRef
Hemodialysis patients with allergic reactions to dialysate whose symptoms improved without dialysate change：Two case reports
Hisato Shima, Yoko Nishiuchi, Yoshio Fukata, Takuya Okamoto, Manabu Tashiro, Tomoko Inoue, Hiroyasu Bando, Hiroyuki Azuma, Naohito Iwasaka, Takuji Ohara, Toshio Doi, Kazuyoshi Okada, Jun Minakuchi
Nihon Toseki Igakkai Zasshi.2024; 57(1): 23. CrossRef
Clinical Features of Thiopurine-Induced Acute Pancreatitis: Comparison Between Patients With and Without Inflammatory Bowel Disease
Tomofumi Oizumi, Yosuke Toya, Shunichi Yanai, Takayuki Matsumoto
Crohn's & Colitis 360.2024;[Epub] CrossRef
Allergic clinical symptoms and distribution of stimulation index of drug lymphocyte stimulation test for local anesthetics
Yukiko Baba, Yu Sato, Ken Takahashi, Takaya Ito, Ryo Wakita, Shigeru Maeda
Oral and Maxillofacial Surgery.2024;[Epub] CrossRef
Lymphocyte stimulation test for diagnosing hen’s egg yolk–induced enterocolitis syndrome
Naoki Kajita, Go Kusakawa, Hiroki Seto, Keiko Hirao, Shoko Yokoyama, Emi Morikawa, Kumiko Morita, Masami Narita, Koichi Yoshida
Journal of Allergy and Clinical Immunology: Global.2023; 2(4): 100138. CrossRef
Risk factors for intolerance of oral 5‐aminosalicylic acid preparations in pediatric ulcerative colitis
Naoki Abe, Naomi Iwata, Ryuhei Yasuoka, Daisuke Nishida, Asami Oohara, Haruna Nakaseko, Shiro Sugiura, Shinji Kawabe
Pediatrics International.2023;[Epub] CrossRef
Pulmonary Manifestations of Inflammatory Bowel Disease and Treatment Strategies
Subha Ghosh, Himanshu Deshwal, Rebecca Haraf, Shine Raju, Mnahi Bin Saeedan, Pralay Sarkar, Thomas Gildea, Carol F. Farver, Atul C. Mehta
CHEST Pulmonary.2023; 1(3): 100018. CrossRef
Significance of 5-Aminosalicylic Acid Intolerance in the Clinical Management of Ulcerative Colitis
Yohei Mikami, Junya Tsunoda, Shohei Suzuki, Ichiro Mizushima, Hiroki Kiyohara, Takanori Kanai
Digestion.2023; 104(1): 58. CrossRef
The Forefront of Drug Therapy for Ulcerative Colitis
Tadakazu Hisamatsu, Daisuke Saito, Minoru Matsuura
Nippon Daicho Komonbyo Gakkai Zasshi.2023; 76(10): 580. CrossRef
Genetic Background of Mesalamine-induced Fever and Diarrhea in Japanese Patients with Inflammatory Bowel Disease
Kaoru Suzuki, Yoichi Kakuta, Takeo Naito, Tetsuya Takagawa, Hiroyuki Hanai, Hiroshi Araki, Yu Sasaki, Hirotake Sakuraba, Makoto Sasaki, Tadakazu Hisamatsu, Satoshi Motoya, Takayuki Matsumoto, Motoyuki Onodera, Yoh Ishiguro, Hiroshi Nakase, Akira Andoh, Sa
Inflammatory Bowel Diseases.2022; 28(1): 21. CrossRef
A complicated case of Serratia marcescens catheter-related bloodstream infection misdiagnosed as hypersensitivity reactions to bicarbonate dialysate containing acetate
Hisato Shima, Takuya Okamoto, Tomoko Inoue, Manabu Tashiro, Yusaku Tanaka, Norimichi Takamatsu, Seiichiro Wariishi, Kazuhiko Kawahara, Kazuyoshi Okada, Jun Minakuchi
CEN Case Reports.2022; 11(1): 55. CrossRef
Cyanamide-induced oral lichenoid drug reaction: Case report and literature review
Yurie Akiyama, Yusuke Oomura, Masahiro Okamura, Chiho Hiraga-Kondo, Taiki Suzuki, Kazumichi Sato, Shinichi Takahashi, Takeshi Nomura
Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology.2022; 34(2): 209. CrossRef
5‐Aminosalicylic acid‐induced pericarditis in pediatric Crohn’s disease
Yuki Toguchi, Kahoru Fukuoka‐Araki, Kei Matayoshi, Saori Kinjo, Toshifumi Yodoshi
Pediatrics International.2022;[Epub] CrossRef
Hematochezia Due to Panitumumab-induced Colitis with Vitamin K Deficiency
Hotaka Tamura, Koji Nakashima, Naomi Uchiyama, Souichiro Ogawa, Hiroshi Hatada, Naoki Yoshida, Keisuke Uchida, Yoshinori Ozono, Hiroyuki Tanaka, Koji Yamamto, Hiroshi Kawakami
Internal Medicine.2022; 61(10): 1503. CrossRef
A Case of Stevens–Johnson Syndrome Complicated with Multimatrix System Mesalamine in Ulcerative Colitis
Mimari Kanazawa, Keiichi Tominaga, Akira Kanamori, Takanao Tanaka, Satoshi Masuyama, Shoko Watanabe, Keiichiro Abe, Akira Yamamiya, Kenichi Goda, Atsushi Irisawa
Medicina.2022; 58(2): 276. CrossRef
A Review of Extraintestinal Manifestations & Medication-Induced Myocarditis and Pericarditis in Pediatric Inflammatory Bowel Disease
Kevin Cesa, Catherine Cunningham, Tyler Harris, Whitney Sunseri
Cureus.2022;[Epub] CrossRef
Retrospective investigation of mesalamine intolerance in patients with ulcerative colitis
Yuki Minagawa, Kazuhiko Uchiyama, Tomohisa Takagi, Katsura Mizushima, Kohei Asaeda, Mariko Kajiwara-Kubota, Saori Kashiwagi, Yuma Hotta, Makoto Tanaka, Ken Inoue, Osamu Dohi, Tetsuya Okayama, Naohisa Yoshida, Kazuhiro Katada, Kazuhiro Kamada, Takeshi Ishi
Journal of Clinical Biochemistry and Nutrition.2022; 71(3): 249. CrossRef
Multicenter survey on mesalamine intolerance in patients with ulcerative colitis
Sakiko Hiraoka, Akiko Fujiwara, Tatsuya Toyokawa, Reiji Higashi, Yuki Moritou, Shinjiro Takagi, Kazuhiro Matsueda, Seiyuu Suzuki, Jiro Miyaike, Toshihiro Inokuchi, Masahiro Takahara, Jun Kato, Hiroyuki Okada
Journal of Gastroenterology and Hepatology.2021; 36(1): 137. CrossRef
Maternal mesalazine-induced neonatal gastrointestinal bleeding
Kohichiroh Nii, Kaoru Okazaki, Hitoshi Okada, Toru Kuboi
BMJ Case Reports.2021; 14(4): e238743. CrossRef
Evidence-based clinical practice guidelines for inflammatory bowel disease 2020
Hiroshi Nakase, Motoi Uchino, Shinichiro Shinzaki, Minoru Matsuura, Katsuyoshi Matsuoka, Taku Kobayashi, Masayuki Saruta, Fumihito Hirai, Keisuke Hata, Sakiko Hiraoka, Motohiro Esaki, Ken Sugimoto, Toshimitsu Fuji, Kenji Watanabe, Shiro Nakamura, Nagamu I
Journal of Gastroenterology.2021; 56(6): 489. CrossRef
Pharmacogenetics-based personalized treatment in patients with inflammatory bowel disease: A review
Ji Young Chang, Jae Hee Cheon
Precision and Future Medicine.2021; 5(4): 151. CrossRef
Hypersensitivity reactions to bicarbonate dialysate containing acetate: a case report with literature review
Yoko Nishiuchi, Hisato Shima, Yoshio Fukata, Tomohiro Tao, Takuya Okamoto, Norimichi Takamatsu, Kazuyoshi Okada, Jun Minakuchi
CEN Case Reports.2020; 9(3): 243. CrossRef
Anaphylaxis to three humanized antibodies for severe asthma: a case study
Koichi Jingo, Norihiro Harada, Toshihiko Nishioki, Masahiro Torasawa, Tomoko Yamada, Tetsuhiko Asao, Haruhi Takagi, Tomohito Takeshige, Jun Ito, Kazuhisa Takahashi
Allergy, Asthma & Clinical Immunology.2020;[Epub] CrossRef
Mesalazine formulation intolerance due to suspected excipient allergy in the treatment of ulcerative colitis: a case report
Yoshinori Arai, Maiko Ogawa, Fumitsugu Yamane, Natsuki Sumiyoshi, Rikako Arimoto, Yoshitaka Ando, Daisuke Endo, Tatsuya Nakada, Ichiro Sugawara, Hiroshi Yokoyama, Keiko Shimoyama, Hiroko Inomata, Yosuke Kawahara, Masayuki Kato, Seiji Arihiro, Atsushi Hoka
Clinical Journal of Gastroenterology.2020; 13(6): 1200. CrossRef
Mesalazine allergy and an attempt at desensitization therapy in patients with inflammatory bowel disease
Satohiro Matsumoto, Hirosato Mashima
Scientific Reports.2020;[Epub] CrossRef
Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis
Rumiko Tsuboi, Satohiro Matsumoto, Hiroyuki Miyatani, Hirosato Mashima
Internal Medicine.2019; 58(5): 649. CrossRef
Allergic reactions to small-molecule drugs: Will we move from reaction to prediction?
Mark F Bonfiglio, David M Weinstein
American Journal of Health-System Pharmacy.2019; 76(9): 574. CrossRef

10,202 View
251 Download
34 Web of Science
40 Crossref

Focused Review: Intestinal Behçet's Disease

Treatment and outcomes: medical and surgical treatment for intestinal Behçet's disease: Tadakazu Hisamatsu, Mari Hayashida; Intest Res 2017;15(3):318-327. Published online June 12, 2017; DOI: https://doi.org/10.5217/ir.2017.15.3.318

Abstract PDF PubReader ePub

Behçet's disease (BD) is a chronic relapsing disease involving multiple organ systems. BD is characterized clinically by oral and genital aphthae, cutaneous lesions, and ophthalmological, neurological, and/or gastrointestinal manifestations. It is widely recognized that the presence of intestinal lesions may be a poor prognostic factor in intestinal BD, increasing the risk of surgery and decreasing the quality of life. Despite this, the management of intestinal BD has not been standardized. Empirical therapies including 5-aminosalicylic acid and corticosteroids have been used anecdotally to treat intestinal BD, but recent studies have provided evidence for the efficacy of anti-tumor necrosis factor α monoclonal antibodies. The development of agents targeting tumor necrosis factor α continues, it seems likely that they will change the therapeutic strategy and clinical outcomes of intestinal BD and inflammatory bowel disease. Monitoring disease activity such as endoscopic evaluation will become more important to obtain better outcomes. Here, we review current and future perspectives in the treatment and outcomes of intestinal BD.

Citations

Citations to this article as recorded by

Management of Severe Behçet’s Disease
Kerem Abacar, Haner Direskeneli, Fatma Alibaz-Oner
Current Rheumatology Reports.2026;[Epub] CrossRef
Behçet’s disease: incidence, prevalence, and real-word data on the use of biologic agents in Japan
Tadakazu Hisamatsu, Makoto Naganuma, Philippe Pinton, Mitsuhiro Takeno
Journal of Gastroenterology.2025; 60(3): 294. CrossRef
Upper Gastrointestinal Involvement in Behcet’s Disease
Hogyung Jun, Hyun Joo Song, Ji Hwan Mun, Heung Up Kim
The Korean Journal of Gastroenterology.2025; 85(2): 170. CrossRef
Long-Term Outcomes and Clinical Factors Associated with Conventional Therapy Failure in Intestinal Behçet’s Disease: A Retrospective Cohort Study in Japan
Keita Murakami, Junya Arai, Sozaburo Ihara, Yumi Tsuchida, Haruka Tsuchiya, Mayo Tsuboi, Ken Kurokawa, Nobumi Suzuki, Hiroto Kinoshita, Yoku Hayakawa, Keishi Fujio, Mitsuhiro Fujishiro
Digestion.2025; : 1. CrossRef
Impact of age at diagnosis on long‐term prognosis in patients with intestinal Behçet's disease
Ji Young Chang, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Hee Cheon, Jihye Park
Journal of Gastroenterology and Hepatology.2024; 39(3): 519. CrossRef
Behçet's syndrome
Giacomo Emmi, Alessandra Bettiol, Gülen Hatemi, Domenico Prisco
The Lancet.2024; 403(10431): 1093. CrossRef
Neither hepatic steatosis nor fibrosis is associated with clinical outcomes in patients with intestinal Behçet’s disease
Hye Kyung Hyun, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Jae Seung Lee, Hye Won Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim, Jae Hee Cheon
European Journal of Gastroenterology & Hepatology.2024; 36(4): 445. CrossRef
Optimal Treatment Approaches to Intestinal Behçet's Disease Complicated by Myelodysplastic Syndrome: The KASID and KSBD Multicenter Study
Jung-Bin Park, So Jung Han, Seung Bum Lee, Dong Hyun Kim, Jae Hee Cheon, Sung Wook Hwang, Byong Duk Ye, Suk-Kyun Yang, Soo Jung Park, Sang Hyoung Park
Yonsei Medical Journal.2024; 65(5): 265. CrossRef
Behçet disease: epidemiology, classification criteria and treatment modalities
Alia Fazaa, Yasmine Makhlouf, Faiza Ben Massoud, Saoussen Miladi, Hiba Boussaa, Kmar Ouenniche, Leila Souebni, Selma Kassab, Selma Chekili, Kawther Ben Abdelghani, Ahmed Laatar
Expert Review of Clinical Immunology.2024; 20(12): 1437. CrossRef
Risk Factors for Surgery in Patients with Intestinal Behçet’s Disease During Anti-Tumor Necrosis Factor-Alpha Therapy
So Jung Han, Eun Ae Kang, Jihye Park, Soo Jung Park, Jae Jun Park, Tae Il Kim, Won Ho Kim, Jae Hee Cheon
Yonsei Medical Journal.2023; 64(2): 111. CrossRef
Possible Association of Mutations in the MEFV Gene with the Intestinal Phenotype of Behçet’s Disease and Refractoriness to Treatment
Yoki Furuta, Ryosuke Gushima, Hideaki Naoe, Munenori Honda, Yuiko Tsuruta, Katsuya Nagaoka, Takehisa Watanabe, Masakuni Tateyama, Nahoko Fujimoto, Shinya Hirata, Eiko Miyagawa, Komei Sakata, Yumiko Mizuhashi, Mikako Iwakura, Masayuki Murai, Masao Matsuoka
Journal of Clinical Medicine.2023; 12(9): 3131. CrossRef
Immune‐mediated inflammatory diseases of the gastrointestinal tract: Beyond Crohn's disease and ulcerative colitis
Sudheer K Vuyyuru, Saurabh Kedia, Pabitra Sahu, Vineet Ahuja
JGH Open.2022; 6(2): 100. CrossRef
Mucosal healing in intestinal Behçet's disease: A systematic review and meta‐analysis
Liang Gong, Yue Lun Zhang, Lu Xi Sun, Guo Rong Chen, Dong Wu
Journal of Digestive Diseases.2021; 22(2): 83. CrossRef
Experimental Therapeutic Solutions for Behcet’s Disease
Burçin Cansu Bozca, Erkan Alpsoy
Journal of Experimental Pharmacology.2021; Volume 13: 127. CrossRef
Treatment of Behçet's Disease: An Algorithmic Multidisciplinary Approach
Erkan Alpsoy, Pietro Leccese, Giacomo Emmi, Shigeaki Ohno
Frontiers in Medicine.2021;[Epub] CrossRef
Behçet Disease: An Update for Dermatologists
Erkan Alpsoy, Burcin Cansu Bozca, Asli Bilgic
American Journal of Clinical Dermatology.2021; 22(4): 477. CrossRef
Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet’s disease: results from a large real-world observational study
Yasuo Suzuki, Takashi Hagiwara, Mariko Kobayashi, Kazuo Morita, Tomoyo Shimamoto, Toshifumi Hibi
Intestinal Research.2021; 19(3): 301. CrossRef
Is fasting beneficial for hospitalized patients with inflammatory bowel diseases?
Yong Eun Park, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim, Jung Nam Kim, Na Rae Lee, Jae Hee Cheon
Intestinal Research.2020; 18(1): 85. CrossRef
Elevated fecal calprotectin and lactoferrin associated with small intestinal lesions in patients with Behçet disease
Mari Hayashida, Jun Miyoshi, Tatsuya Mitsui, Miki Miura, Daisuke Saito, Akihito Sakuraba, Soko Kawashima, Noriko Ikegaya, Kazuhito Fukuoka, Miho Karube, Yoshinori Komagata, Shinya Kaname, Annabelle A Okada, Shunji Fujimori, Minoru Matsuura, Tadakazu Hisam
Journal of Gastroenterology and Hepatology.2020; 35(8): 1340. CrossRef
Successful combination therapy using adalimumab and 5-aminosalicylic acid for a resistant case of intestinal Behçet’s disease
H. J. Kim, K.‑t. Kim, S.-G. Lee, Y. Kim
Zeitschrift für Rheumatologie.2020; 79(7): 702. CrossRef
Update on the treatment of Behçet’s syndrome
Sinem Nihal Esatoglu, Gulen Hatemi
Internal and Emergency Medicine.2019; 14(5): 661. CrossRef
Behсet's disease: intestinal damage
R. G. Goloeva, Z. S. Alekberova
Rheumatology Science and Practice.2019; 56(6): 767. CrossRef
Intestinal manifestations of Behçet's disease
R G Goloeva, Z S Alekberova, T A Lisitsyna, E A Stepanova, L P Orlova
Terapevticheskii arkhiv.2019; 91(5): 111. CrossRef
The outcomes and risk factors of early readmission in patients with intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon, Yehyun Park, Soo Jung Park, Tae Il Kim, Won Ho Kim
Clinical Rheumatology.2018; 37(7): 1913. CrossRef
Cancer Risk in Patients with Intestinal Behçet’s Disease: A Nationwide Population-Based Study
Minkyung Han, Yoon Suk Jung, Won Ho Kim, Jae Hee Cheon, Sohee Park
Gut and Liver.2018; 12(4): 433. CrossRef
Updated treatment strategies for intestinal Behçet’s disease
Yong Eun Park, Jae Hee Cheon
The Korean Journal of Internal Medicine.2018; 33(1): 1. CrossRef
Small Bowel Lesions Mimicking Crohn’s Disease
David B. Sachar
Current Gastroenterology Reports.2018;[Epub] CrossRef
Anti-Tumor Necrosis Factor Therapy in Intestinal Beh Ccedil;et rsquo;s Disease
Jihye Park, Jae Hee Cheon
Gut and Liver.2018; 12(6): 623. CrossRef

10,298 View
88 Download
25 Web of Science
28 Crossref

First
Prev
Page of 1
Next
Last

Search